Clinical Trials Logo

C3 Glomerulonephritis clinical trials

View clinical trials related to C3 Glomerulonephritis.

Filter by:

NCT ID: NCT01791686 Terminated - Clinical trials for Dense Deposit Disease

Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit Disease

Start date: January 2013
Phase: Phase 1
Study type: Interventional

This study is evaluating the study drug (CDX-1135) in patients with dense deposit disease (DDD). The objective is to evaluate the safety and activity of repeated doses of CDX-1135 in pediatric and adult patients with DDD. After screening, eligible patients will be entered into the Induction Period. The Induction Period is up to 4 weeks. Following normalization of complement activity, patients will enter into the Maintenance Period.The total treatment duration is up to 26 weeks.